Elizabeth Perry1,2, Paul Eggleton2, Anthony De Soyza3,4, David Hutchinson5, Clive Kelly6. 1. Department of Rheumatology, Musgrove Park Hospital, Taunton, Somerset, UK. 2. University of Exeter Medical School, Devon, UK. 3. Lung Immunobiology and Transplantation Group, Institute of Cellular Medicine, Newcastle University, Newcastle, UK. 4. Sir William Leech Centre, Freeman Hospital, Newcastle, UK. 5. Department of Rheumatology, Royal Cornwall Hospital Trust, Truro, UK. 6. Department of Rheumatology, Queen Elizabeth Hospital, Gateshead, UK.
Abstract
AIM: Patients with rheumatoid arthritis (RA) and co-existent bronchiectasis (BRRA) have a five-fold increased mortality compared to rheumatoid arthritis alone. Yet previous studies have found no difference in clinical and serological markers of RA disease severity between BRRA patients and RA alone. However, RA disease activity measures such as Disease Activity Score of 28 joints - C-reactive protein (DAS28-CRP) and anti-cyclic citrullinated peptide antibodies (anti-CCP) have not been studied, so we assessed these parameters in patients with BRRA and RA alone. METHODS: BRRA patients (n = 53) had high-resolution computed tomography proven bronchiectasis without any interstitial lung disease and ≥ 2 respiratory infections/year. RA alone patients (n = 50) had no clinical or radiological evidence of lung disease. DAS28-CRP, rheumatoid factor (immunoglobulin M) and anti-CCP were measured in all patients, together with detailed clinical and radiology records. RESULTS: In BRRA, bronchiectasis predated RA in 58% of patients. BRRA patients had higher DAS28 scores (3.51 vs. 2.59), higher levels of anti-CCP (89% vs. 46%) and rheumatoid factor (79% vs. 52%) (P = 0.003) compared to RA alone. Where hand and foot radiology findings were recorded, 29/37 BRRA (78%) and 13/30 (43%) RA alone had evidence of erosive change (P = 0.003). There were no significant differences between groups in smoking history or disease-modifying anti-rheumatic drug/biologic therapy. CONCLUSIONS: Increased levels of RA disease activity, severity and RA autoantibodies are demonstrated in patients with RA and co-existent bronchiectasis compared to patients with RA alone, despite lower tobacco exposure. This study demonstrates that BRRA is a more severe systemic disease than RA alone.
AIM: Patients with rheumatoid arthritis (RA) and co-existent bronchiectasis (BRRA) have a five-fold increased mortality compared to rheumatoid arthritis alone. Yet previous studies have found no difference in clinical and serological markers of RA disease severity between BRRA patients and RA alone. However, RA disease activity measures such as Disease Activity Score of 28 joints - C-reactive protein (DAS28-CRP) and anti-cyclic citrullinated peptide antibodies (anti-CCP) have not been studied, so we assessed these parameters in patients with BRRA and RA alone. METHODS: BRRA patients (n = 53) had high-resolution computed tomography proven bronchiectasis without any interstitial lung disease and ≥ 2 respiratory infections/year. RA alone patients (n = 50) had no clinical or radiological evidence of lung disease. DAS28-CRP, rheumatoid factor (immunoglobulin M) and anti-CCP were measured in all patients, together with detailed clinical and radiology records. RESULTS: In BRRA, bronchiectasis predated RA in 58% of patients. BRRA patients had higher DAS28 scores (3.51 vs. 2.59), higher levels of anti-CCP (89% vs. 46%) and rheumatoid factor (79% vs. 52%) (P = 0.003) compared to RA alone. Where hand and foot radiology findings were recorded, 29/37 BRRA (78%) and 13/30 (43%) RA alone had evidence of erosive change (P = 0.003). There were no significant differences between groups in smoking history or disease-modifying anti-rheumatic drug/biologic therapy. CONCLUSIONS: Increased levels of RA disease activity, severity and RA autoantibodies are demonstrated in patients with RA and co-existent bronchiectasis compared to patients with RA alone, despite lower tobacco exposure. This study demonstrates that BRRA is a more severe systemic disease than RA alone.
Authors: H Maura Friedlander; Julia A Ford; Alessandra Zaccardelli; Alexsandra V Terrio; Michael H Cho; Jeffrey A Sparks Journal: Expert Rev Clin Immunol Date: 2020-01-06 Impact factor: 4.473
Authors: Jill A Poole; Geoffrey M Thiele; Katherine Janike; Amy J Nelson; Michael J Duryee; Kathryn Rentfro; Bryant R England; Debra J Romberger; Joseph M Carrington; Dong Wang; Benjamin J Swanson; Lynell W Klassen; Ted R Mikuls Journal: J Bone Miner Res Date: 2019-06-24 Impact factor: 6.741
Authors: Ted R Mikuls; Rohit Gaurav; Geoffrey M Thiele; Bryant R England; Madison G Wolfe; Brianna P Shaw; Kristina L Bailey; Todd A Wyatt; Amy J Nelson; Michael J Duryee; Carlos D Hunter; Dong Wang; Debra J Romberger; Dana P Ascherman; Jill A Poole Journal: Int Immunopharmacol Date: 2021-08-27 Impact factor: 4.932
Authors: Melissa J McDonnell; Stefano Aliberti; Pieter C Goeminne; Marcos I Restrepo; Simon Finch; Alberto Pesci; Lieven J Dupont; Thomas C Fardon; Robert Wilson; Michael R Loebinger; Dusan Skrbic; Dusanka Obradovic; Anthony De Soyza; Chris Ward; John G Laffey; Robert M Rutherford; James D Chalmers Journal: Lancet Respir Med Date: 2016-11-16 Impact factor: 30.700
Authors: Krista Makin; Tracie Easter; Monica Kemp; Peter Kendall; Max Bulsara; Sophie Coleman; Graeme J Carroll Journal: PLoS One Date: 2019-04-10 Impact factor: 3.240
Authors: Valerie R Wiersma; Alex Clarke; Simon D Pouwels; Elizabeth Perry; Trefa M Abdullah; Clive Kelly; Anthony De Soyza; David Hutchinson; Paul Eggleton; Edwin Bremer Journal: Int J Mol Sci Date: 2019-08-19 Impact factor: 5.923